CAS: 32795-44-1; N-Acetylprocainamide

上下游产品

CAS号201230-82-2 carbon monoxide | CAS号103-88-8 4'-溴乙酰苯胺 | CAS号100-36-7 N,N-二乙基乙二胺 | CAS号122-85-0 对乙酰氨基苯甲醛 | CAS号614-39-1 盐酸普鲁卡因胺 | CAS号75-36-5 乙酰氯

📜N,N-二乙基乙二胺置于叔丁基过氧化氢,N-氯代丁二酰亚胺,Copper(Ll) Sulfate Pentahydrate体系中,化学反应 3.0H,反应生成 N-乙酰普鲁卡因胺
参考文献:Copper-Catalyzed One-Pot Oxidative Amidation Of Alcohol To Amide Via C-h Activation
标题:Copper-Catalyzed One-Pot Oxidative Amidation Of Alcohol To Amide Via C-h Activation
摘要:铜催化的一锅法氧化酰胺化反应,使用从多种类型的一级和二级胺现场制备的n-氯胺与脂肪族和芳香族醇反应,在温和条件下形成酰胺.
DOI:10.1039/c6Ra20732D

专利信息

专利号:US-4795828-A
优先权日:1983-01-03
标题 :Functionalized intermediate for the synthesis of alpha-functionalized derivatives and labeled conjugates of procaimamide and NAPA
发明人：BUCKLER ROBERT T; WARD FREDERICK E
权利人:MILES INC
摘要:Procainamide and N-acetylprocainamide (NAPA) immunogens, antibodies prepared therefrom, labeled conjugates, synthetic intermediates, and the use of such antibodies and labeled conjugates in immunoassays for determining the respective drugs. The immunogens comprise the drugs coupled at the alpha -position of the amide side chain to an immunogenic carrier material. The labeled conjugates and synthetic intermediates similarly are alpha -position derivatives of the drugs or precursors thereof. The antibodies and labeled conjugates are particularly useful in homogeneous nonradioisotopic immunoassays for measuring the respective drugs in biological fluids such as serum.

专利号:US-5525474-A
优先权日:1994-01-31
标 题 :Piperidine analogs and conjugates of procainamide and NAPA
发明人：SIGLER GERALD F; WALTER CHARLES F; GLANCY TODD; HUBER ERASMUS; KLEIN FRANK E
权利人:BOEHRINGER MANNHEIM CORP
摘要:Novel derivatives of procainamide and N-acetylprocainamide (NAPA) are disclosed having the following formula: wherein: X=hydrogen or acetyl; n=1 to p where p=MW of Z/1000; Z=a poly(amino acid) or polysaccharide; and R3=a bond or aving 2 to 10 carbon atoms. The derivatives include maleimide conjugates of proteins or poly(amino acids), enzymes, enzyme donor polypeptides and labeling substances. Novel activated hapten intermediates useful in the preparation of the conjugates and methods for synthesis of the hapten intermediates and derivatives are also disclosed.

专利号:US-5439798-A
优先权日:1993-12-17
标 题:Maleimide adduct conjugates of procainamide and NAPA
发明人：SIGLER GERALD F; WALTER CHARLES F; DURANT CHARLES E; GLANCY TODD; KLEIN FRANK E; DORN ALLAN R
权利人:BOEHRINGER MANNHEIM CORP
摘要:Novel derivatives of procainamide and N-acetylprocainamide (NAPA) are disclosed having the following formula: +TR wherein: X=hydrogen or acetyl; R1=an alkyl group having 1 to 3 carbon atoms; m=an integer from 2 to 10; R2=an alkyl, cycloalkyl or aryl group having 2 to 10 carbon atoms; Z=a poly(amino acid); and n=1 to p where p=MW of Z/1000. The derivatives include maleimide conjugates of proteins or poly(amino acids), enzymes, enzyme donor polypeptides and labeling substances. Novel activated hapten intermediates useful in the preparation of the conjugates and methods for synthesis of the hapten intermediates and derivatives are also disclosed.

专利号:US-6187756-B1
优先权日:1996-09-05
标 题 :Composition and methods for treatment of neurological disorders and neurodegenerative diseases
发明人：LEE ROBERT K K; WURTMAN RICHARD J
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:It has been discovered that the stimulation of β-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising β-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by β-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E 2 (PG E 2 ), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of β-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E 2 , forskolin, or nicotine ditartrate is inhibited by immunosuppressants or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

专利号:US-6469055-B2
优先权日:1996-09-05
标题 :Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
发明人：LEE ROBERT K K; WURTMAN RICHARD J
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:It has been discovered that the stimulation of β-adrenergic receptors, which activate cAMP formation, give rise to increased APP and GFAP synthesis in astrocytes. Hence, the in vitro or in vivo exposure of neuronal cells to certain compositions comprising β-adrenergic receptor ligands or agonists, including, e.g., norepinephrine, isoproterenol and the like, increases APP mRNA transcription and consequent APP overproduction. These increases are blocked by β-adrenergic receptor antagonists, such as propranolol. The in vitro or in vivo treatment of these cells with 8Br-cAMP, prostaglandin E 2 (PG E 2 ), forskolin, and nicotine ditartrate also increased APP synthesis, including an increase in mRNA and holoprotein levels, as well as an increase in the expression of glial fibrillary acidic protein (GFAP). Compositions and methods are disclosed of regulating APP overexpression and mediating reactive astrogliosis through cAMP signaling or the activation of β-adrenergic receptors. It has further been found that the increase in APP synthesis caused by 8Br-cAMP, PG E 2 , or forskolin is inhibited by immunosuppressants, immunophilin ligands, or anti-inflammatory agents, such as cyclosporin A, and FK-506 (tacrolimus), as well as ion-channel modulators, including ion chelating agents such as EGTA, or calcium/calmodulin kinase inhibitors, such as KN93. The present invention has broad implications in the alleviation, treatment, or prevention of neurological disorders and neurodegenerative diseases, including Alzheimer's Disease.

专利号:US-5362625-A
优先权日:1991-05-15
标 题:Methods and compositions for enzyme complementation assays using the omega region of β-galactosidase
发明人：KREVOLIN MARK; KATES DAVID
权利人:MICROGENICS CORP
摘要:The use of omega-acceptor and omega-donor polypeptides (comprising about two-thirds and one-third of the beta -galactosidase molecule amino and carboxyl termini, respectively), prepared by recombinant DNA techniques, DNA synthesis, or chemical polypeptide synthesis techniques, which are capable of interacting to form an active enzyme complex having catalytic activity characteristic of beta -galactosidase, is described along with improved methods and novel compositions for enzyme complementation assays for qualitative and quantitative determination of a suspected analyte in a sample.